Asahi Kasei Corporation (AHKSF)
| Market Cap | 14.78B +58.2% |
| Revenue (ttm) | 19.34B +1.2% |
| Net Income | 998.67M +17.6% |
| EPS | 0.74 +19.4% |
| Shares Out | n/a |
| PE Ratio | 14.80 |
| Forward PE | n/a |
| Dividend | 0.27 (2.39%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 5,200 |
| Open | 11.20 |
| Previous Close | n/a |
| Day's Range | 11.05 - 11.40 |
| 52-Week Range | 6.55 - 11.84 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About Asahi Kasei
Asahi Kasei Corporation engages in material, homes, healthcare businesses. The company offers Pimel photosensitive polyimide/PBO precursor, a liquid photosensitive material for buffer coating and packaging applications; Sunfort dry film photoresist to form circuit patterns on printed wiring boards; Novacure, a latent curing agent for epoxy resin with storage stability; glass fabric for printed circuit boards; plastic optical fiber; suede products under the Dinamica name; Microza UF and MF industrial membranes and systems; Aciplex membranes, pro... [Read more]
Financial Performance
In fiscal year 2026, Asahi Kasei's revenue was 3.07 trillion, an increase of 1.22% compared to the previous year's 3.04 trillion. Earnings were 158.79 billion, an increase of 17.63%.
Financial numbers in JPY Financial StatementsNews
EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei's Novel Electrolyte Acetolyte™
DUSSELDORF, Germany--(BUSINESS WIRE)--EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell which incorporates Asahi Kasei's novel Acetolyte™.
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute – A Major Milestone for More Efficient and Safer Cancer Treatments
TOKYO--(BUSINESS WIRE)--Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
TOKYO--(BUSINESS WIRE)--Asahi Kasei has combined the features of its photosensitive polyimide (PSPI) and dry film photoresist (DFR) into a new photosensitive film.
Asahi Kasei Microdevices Debuts AK491x Premium Audio Op Amps at HIGH END Vienna 2026
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices (AKM) has unveiled the AK491x series of premium audio operational amplifiers (op amps).
$1.5B battery separator plant in Port Colborne still a go despite Honda suspending electric vehicle plans
Work on the $1.56-billion Asahi Kasei battery separator plant in Port Colborne, Ont., is proceeding despite Honda Canada's announcement it has indefinitely suspended its $15-billion electric vehicle (...
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
Asahi Kasei Slides: Q4 2026
Asahi Kasei has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Asahi Kasei Quarterly report: Q4 2026
Asahi Kasei has published its Q4 2026 quarterly earnings report on May 11, 2026.
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound.
Asahi Kasei Slides: Investor presentation
Asahi Kasei has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO
MUNICH & HOUSTON--(BUSINESS WIRE)--KEWAZO, the robotics company transforming heavy industry worldwide, today announced a new funding round backed by Chevron Technology Ventures, Asahi Kasei, Benson Ca...
Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland's First Commercial Hydrogen Refueling Station
TOKYO--(BUSINESS WIRE)--Asahi Kasei has started the installation of an Aqualyzer™-C3 at Finland's first commercial hydrogen refueling station in Jyväskylä.
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U...
Asahi Kasei Slides: Acquisition presentation
Asahi Kasei has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma announced an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine.
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.
Asahi Kasei Quarterly report: Q3 2026
Asahi Kasei has published its Q3 2026 quarterly earnings report on February 3, 2026.
Asahi Kasei Slides: Q3 2026
Asahi Kasei has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 3, 2026.
Asahi Kasei Develops PFAS-Free PA66 Offering Low-Friction and High-Load Performance
DUESSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei announced the development of a new PFAS-free polyamide (PA) engineered specifically for demanding low-friction applications.
ZOLL Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category
CHELMSFORD, Mass. & TOKYO--(BUSINESS WIRE)--Asahi Kasei announced that ZOLL® Medical has launched the next-generation LifeVest® wearable cardioverter defibrillator (WCD) in the U.S.
Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark
TOKYO--(BUSINESS WIRE)--Asahi Kasei Pharma Corporation has announced plans to relocate its R&D hub from Izunokuni City, Shizuoka Prefecture to Shonan Health Innovation Park.
Asahi Kasei Microdevices and Aizip Deliver Transformative AI-Enhanced Sensing Solutions
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices (AKM) and Aizip have partnered to showcase two innovations in AI-enhanced sensing.
Asahi Kasei Receives 2025 TSMC Excellent Performance Award in Recognition of Its PIMEL™ Photosensitive Dielectric for Advanced Packaging Material
TOKYO--(BUSINESS WIRE)--Asahi Kasei received a 2025 TSMC Excellent Performance Award for “Excellent Technology Development and Production Support.".